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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumorsof thedigestive tract.
Almost allGISTs express theKIT protein (CD 117), the
product of the c-KIT protoncogene that is a trans-
membrane receptor for the stem cell factor (SCF or
KIT ligand) with a tyrosine kinase domain. The
tumorigenesis of GISTs involves mutations in the c-
KIT protoncogene, resulting in ligand-independent18, 02036 Passo Corese,
39 2203940; fax: þ39 6
par in i@un i roma1. i t ,
6 Published by Elsevier Ltd onconstitutive activation, i.e. activation in the ab-
sence of SCF of the tyrosine kinase receptor KIT.
About 70e80% of the GISTs are also positive for CD34
and approximately 30% are positive for Smooth
Muscle Actin (SMA), whereas a large majority of
tumors is negative for S-100 protein and desmin.1
Metastatic spread of GISTs is usually to the liver,
omentum and/or peritoneum as emphasized by
Barnes et al.2 in their interesting review.Case report
A 69-year-old man was referred to the Medical
Department of ‘‘La Sapienza University’’ forbehalf of Surgical Associates Ltd.
Figure 1 Ultrasonographic image of the right thyroid
lobe mass.
Figure 2 (a) Hematoxylineeosin stain. Right thyroid
lobe mass diagnosed as anaplastic carcinoma; (b) immu-
nohistochemistry. Right thyroid lobe mass: focal positivity
for c-KIT suggestive for GISTs.
416 N. Peparini et al.evaluation of weight loss, asthenia, and fits of dry
cough and dyspnea. Physical examination and sev-
eral imaging procedures, including chest and tho-
racic inlet X-ray, cervical ultrasonography, cervical
and thoracic CT scan, revealed a multinodular
plunging goiter with left tracheal dislocation be-
cause of a prevalent nodule of the right thyroid lobe
(Fig. 1). An iron deficiency anemia (Hb: 10.5 g/dl)
was revealed by routine blood tests. Normal values
of the serum level of FT3, FT4, TG, TSH, calcitonin
and antithyroid peroxidase antibodies were pres-
ent; the values of blood gas and the ventilatory
function tests resulted in the normal range. The
patient did not consent to esophagogastroduodeno-
scopy (EGDS). No masses were demonstrated by
colonoscopy, abdominopelvic ultrasonography,
and abdominopelvic CT. In August 2000 a total
thyroidectomy was performed at the Department
of Surgical Sciences of ‘‘La Sapienza University’’.
Definitive histology revealed a colloid cyst and an
hyperplastic benign nodule in the left thyroid lobe
and a largely necrotic anaplastic carcinoma
(Fig. 2a) 5 cm in maximum size confirmed by immu-
nohistochemical negativity for calcitonin (CT), car-
cinoembryonic antigen (CEA), neuron-specific
enolase (NSE), chromogranin A (CgA), thyroglobulin
(TG), and cytokeratin (CK). In the postoperative
course, because of increasing inappetence and
onset of dyspepsia, the patient consented to
EGDS: endoscopic biopsies of an ulcerated polypoid
mass that was revealed at the lower third of the
stomach were suggestive of a poorly differentiated
carcinoma. Twenty days after thyroidectomy, a sub-
total gastrectomy and a jejunal resection were per-
formed because the surgical exploration revealed
a little jejunal mass that at frozen section examina-
tion showed a stromal tumor. Pathological examina-
tion showed a necrotic polypoid brown-dark
ulcerated mass, 5.5 cm 3 cm 2 cm in size,infiltrating full-thickness the lower gastric wall
and a protruding ulcerated mass, 1.2 cm in greatest
diameter penetrated full-thickness the jejunal
wall. Histological examination of the formalin-fixed
specimen indicated that gastric and jejunal masses
were stromal cell neoplasms with high mitotic rate
(>5 50 high power fields) showing lymphatic and
venous invasion and immunohistochemical focal
positivity for VIM, CD34, c-KIT, S-100 and SMA and
immunonegativity for CK and LCA. Definitive diag-
nosis of gastric and jejunal high-grade GISTs was
made and the morphological and immunophenotyp-
ical features of the diagnosed anaplastic thyroid
carcinoma were reconsidered. Based on the micro-
scopic features of the revised histological sections
and on the additional immunohistochemistry show-
ing diffuse positivity for VIM, focal positivity for
c-KIT (Fig. 2b), CD34, S-100 and SMA and negativity
for LCA, the thyroid tumor was reinterpreted as
a synchronous thyroid metastasis from high-grade
GISTs. The patient died nine months later because
of neoplastic spread.
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Recent progresses in medical treatment of GISTs
indicate that STI571 (Imatinib mesylate) therapy is
effective in metastatic and recurrent GISTs: the
tyrosine kinase inhibitor, STI571, selectively sup-
presses the activity of ABL, PDGFR and KIT tyrosine
kinases. Heinrich et al.3 suggested that GISTs ex-
press KIT or PDGFRA oncoproteins and also that
KIT and PDGFRA mutations are mutually exclusive
oncogenic events in GISTs and have similar biolog-
ical consequences; thus GISTs also showing low or
undetectable KIT expression but strongly PDGFRA
expression could be sensitive to Imatinib. Nunobe
et al.4 showed that in metastatic GISTs, surgical
treatment seems to be difficult due to the high fre-
quency of repeated metastasis to various sites,
therefore, they pointed out that adjuvant therapy
must be required in the treatment of metastatic
GISTs. In the study by Bauer et al.5 viable tumor
cells were found in all but one resected specimen
of patients with metastatic GIST treated by preop-
erative Imatinib therapy suggesting that despite
favorable radiological or clinical responses, Imati-
nib is unlikely to induce pathological complete
response. However, an early aggressive surgery is
indicated for patients with metastatic GISTs until
definitive results from prospective trials investigat-
ing a combined surgical and pre- or postoperative
Imatinib treatment are available.2,5 The impor-
tance of a multidisciplinary approach using both
surgery and Imatinib therapy is also emphasized in
the study by Heinrich and Corless.6 Pathological
complete response after Imatinib treatment was
reported in a metastatic gastrointestinal stromal
tumor.7 Barnes et al.2 pointed out that Imatinib
therapy can inhibit neoplastic proliferation and
induce shrinkage of metastatic GIST enabling re-
section and that surgery remains an important
treatment in metastatic GIST providing the bestpalliation and eliminating the resistant neoplastic
clones. Irving et al.8 reported five cases of ovarian
metastasis of GISTs: most of these were initially
misdiagnosed as tumors of other types with signifi-
cant therapeutic and prognostic implications be-
cause of medical treatment now available for GISTs.
To our knowledge, this is the first report of
thyroid metastasis spreading from gastrointestinal
stromal tumors. Unfortunately, when our patient
was treated, the benefits of the Imatinib therapy
for metastatic GISTs were not yet known.References
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